Meta分析:脂肪性肝病相关遗传风险等位基因对纵向结局的影响
该系统综述与Meta分析检索截至2024年7月4日的PubMed、Embase和Medline数据库,纳入40项成人脂肪性肝病研究,评估PNPLA3、TM6SF2、MBOAT7、HSD17B13和GCKR变异对肝硬化、主要不良肝脏结局、心血管疾病、肝外恶性肿瘤及死亡的影响。PNPLA3-rs738409-GG、TM6SF2-rs58542926-CT或TT及MBOAT7-rs641738-TT与部分肝脏结局显著相关,对肝外结局影响较小。作者认为常规基因分型可能改善晚期肝病患者的风险分层。
要点
- PNPLA3-rs738409-GG vs CC与主要不良肝脏结局、肝病死亡及全因死亡风险升高相关。
- TM6SF2-rs58542926-CT或TT vs CC与肝细胞癌风险升高相关。
- MBOAT7-rs641738-TT vs CC与主要不良肝脏结局风险升高相关。
核心结论
- PNPLA3、TM6SF2和MBOAT7变异与肝脏结局显著相关,尤其在基线晚期肝病时,对肝外结局影响较小。
- 作者认为常规基因分型可能改善晚期肝病脂肪性肝病患者的风险分层。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Medline数据库自建库至2024年7月4日,纳入40项成人脂肪性肝病研究。
主要发现
- PNPLA3-rs738409-GG基因型(vs CC基因型)与主要不良肝脏结局发生率显著升高相关(sHR 2.30 [95% CI 1.66-3.18])。
- PNPLA3-rs738409-GG基因型(vs CC基因型)与肝病死亡风险显著升高相关(sHR 2.83 [95% CI 1.58-5.06])。
- PNPLA3-rs738409-GG基因型(vs CC基因型)与全因死亡风险升高相关(HR 1.24 [95% CI 1.04-1.47])。
- TM6SF2-rs58542926-CT或TT基因型(vs CC基因型)与肝细胞癌发生率升高相关(sHR 2.12 [95% CI 1.66-2.70])。
- MBOAT7-rs641738-TT基因型(vs CC基因型)与主要不良肝脏结局显著相关(sHR 1.21 [95% CI 1.1-1.33])。
临床怎么用
- 作者认为,常规基因分型可能改善晚期肝病脂肪性肝病患者的风险分层。
局限性
- 文献存在结局报告不一致和纤维化分期分布不一致的问题。
- 关于酒精相关性肝病和非PNPLA3遗传变异的研究相对较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic variants associated with risk of steatotic liver disease (SLD) may also influence clinical events. AIMS: To perform a systematic review and meta-analysis to determine the impact of SLD-associated genetic variants on hepatic and extrahepatic complications in SLD. METHODS: We searched PubMed, Embase and Medline databases from inception through July 4th, 2024 for studies on adults with SLD that reported effects of PNPLA3, TM6SF2, MBOAT7, HSD17B13 and GCKR variants on the incidence of cirrhosis, major adverse liver outcomes (MALO), cardiovascular disease, extrahepatic malignancy and overall or cause-specific mortality. We pooled hazard ratios and 95% confidence intervals from these outcomes to allow for comparison. RESULTS: We screened 6475 studies and included 40 in the final analysis. PNPLA3-rs738409-GG genotype (vs. CC genotype) was associated with significantly higher incidence of MALO (sHR 2.30 [95% CI 1.66-3.18]), liver-related mortality (sHR 2.83 [95% CI 1.58-5.06]) and all-cause mortality (HR 1.24 [95% CI 1.04-1.47]). TM6SF2-rs58542926-CT or TT (vs. CC) genotype was associated with a higher incidence of hepatocellular carcinoma (sHR 2.12 [95% CI 1.66-2.70]). MALO was significantly associated with MBOAT7 -rs641738-TT (vs. CC) genotype (sHR 1.21 [95% CI 1.1-1.33]). Limitations in the literature include inconsistent outcome reporting and distribution of fibrosis stage, and a relative paucity of studies on both alcohol-associated liver disease and non-PNPLA3 genetic variants. CONCLUSIONS: Variants in PNPLA3, TM6SF2 and MBOAT7 are significantly associated with hepatic outcomes, especially with advanced baseline liver disease, with modest effects on extrahepatic outcomes. Routine genotyping may improve risk stratification in SLD patients with advanced liver disease.
引用
- Kubina M, Prasitsumrit V, Tan J, et al. Meta-Analysis: Effects of Steatotic Liver Disease-Associated Genetic Risk Alleles on Longitudinal Outcomes. Aliment Pharmacol Ther. 2025. PMID: 40580198. doi:10.1111/apt.70256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。